Analysis of Inflammatory and Immune Response Biomarkers in Sputum and Exhaled Breath Condensate by a Multi-Parametric Biochip Array in Cystic Fibrosis

Abstract

Cystic Fibrosis (CF) lung disease is characterized by high levels of cytokines and chemokines in the airways, producing chronic inflammation. Non-invasive biomarkers, which are also specific for the inflammatory and immune responses, are urgently needed to identify exacerbations and evaluate therapeutic efficacy. The aim of this study is to evaluate the association of sputum and exhaled breath condensate (EBC) biomarker changes with clinical exacerbation and response to therapy. We studied the simultaneous presence and concentration of twelve cytokines and growth factors (EGF, IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IFN-γ, MCP-1, TNF-α and VEGF) by a multi-parametric biochip array in sputum and EBC of 24 CF patients before, after 6 and 15 days of therapy, and 15 days after the end of treatment for an acute exacerbation. Correlations with functional respiratory tests (FEV₁, FVC) and the systemic marker C-reactive protein (CRP) were looked for. In sputum, before therapy, VEGF and IL-1β levels positively correlated with the respiratory function and CRP. Sputum IL-1α, IL-1β IL-4, IL-10, TNF-α, and VEGF significantly decreased, while EGF increased, during therapy. IL-8 and IL-4 levels negatively correlated with the respiratory function at 15 and 30 days from the start of therapy, respectively. IL-4, IL-6, IL-10 and TNF-α positively correlated with CRP during therapy. Although some EBC biomarkers correlated with respiratory function and CRP, no significant associations with these clinical parameters were found. Sputum IL-1β and VEGF might be considered biomarkers of an acute exacerbation in CF patients. A panel of sputum cytokines and growth factors may better describe the response to intravenous antibiotic treatment of CF than one single systemic marker.

Keywords

biomarkers cystic fibrosis exhaled breath condensate inflammation sputum

References

Davis

Drumm

Konstan

. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154:1229–56.

De Rose

. Mechanisms and markers of airway inflammation in cystic fibrosis. Eur Respir J 2002; 19:333–40.

Elizur

Cannon

Ferkol

. Airway inflammation in cystic fibrosis. Chest 2008; 133:489–95.

Sagel

. Noninvasive biomarkers of airway inflammation in cystic fibrosis. Curr Opin Pulm Med 2003; 9:516–21.

Rosenfeld

. An overview of endpoints for cystic fibrosis clinical trials: One size does not fit all. Proc Am Thorac Soc 2007; 4:299–301.

Colombo

Costantini

Rocchi

Cariani

Garlaschi

Tirelli

. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmunol 2005; 40:15–21.

Cunningham

McColm

Mallinson

Boyd

Marshall

. Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosis. Pediatr Pulmonol 2003; 36:43–8.

Downey

Brockbank

Martin

Ennis

Elborn

. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol 2007; 42:729–35.

Carpagnano

Barnes

Geddes

Hodson

Kharitonov

. Increased leukotrierie B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis. Am J Respir Crit Care Med 2003; 167:1109–12.

10.

Robroeks

Rosias

Van Vliet

Jobsis

Yntema

Brackel

. Biomarkers in exhaled breath condensate indicate presence and severity of cystic fibrosis in children. Pediatr Allergy Immunol 2008; 19:652–9.

11.

Cunningham

McColm

Greening

Marshall

. Measurement of inflammatory markers in the breath condensate of children with cystic fibrosis. Eur Respir J 2000; 15:955–7.

12.

Wolter

Rodwell

Bowler

McCormack

. Cytokines and inflammatory mediators do not indicate acute infection in cystic fibrosis. Clin Diagn Lab Immunol 1999; 6:260–5.

13.

Doring

Conway

Heijerman

HGM

Hodson

Hoiby

Smyth

. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis. A European consensus. Eur Respir J 2000; 16:749–67.

14.

American Thoracic Society. Standardization of spirometry. Am J Respir Crit Care Med 1995; 152: 1107–36.

15.

Tirelli

Colombo

Torresani

Cariani

Arnaboldi

Conese

. Validation of an automated sensitive immunoassay for quantitation of cytokines in the sputum of cystic fibrosis patients. Clin Chem Lab Med 2007; 45:108–11.

16.

Horvath

Hunt

Barnes

Alving

Antczak

Baraldi

. Exhaled breath condensate: Methodological recommendations and unresolved questions. Eur Respir J 2005; 26:523–48.

17.

FitzGerald

Lamont

McConnell

Benchikh

. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem 2005; 51:1165–76.

18.

FitzGerald

McConnell

Huxley

. Simultaneous analysis of circulating human cytokines using a high-sensitivity cytokine biochip array. J Proteome Res 2008; 7:450–5.

19.

Molloy

McConnell

Lamont

FitzGerald

. Automation of biochip array technology for quality results. Clin Chem Lab Med 2005; 43:1303–13.

20.

Levy

Kalish

Huntington

Weller

Gerard

Silverman

. Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatr Pulmonol 2007; 42:256–62.

21.

Dinarello

. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27:519–50.

22.

Bonfield

Konstan

Berger

. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999; 104: 72–8.

23.

Barleon

Sozzani

Zhou

Weich

Mantovani

Marme

. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87:3336–43.

24.

Celletti

Waugh

Amabile

Brendolan

Hilfiker

Dake

. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7:425–9.

25.

McColley

Stellmach

Boas

Jain

Crawford

. Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation. Am J Respir Crit Care Med 2000; 161:1877–80.

26.

Shute

Marshall

Bodey

Bush

. Growth factors in cystic fibrosis - when more is not enough. Paediatr Respir Rev 2003; 4:120–7.

27.

Moser

Kjaergaard

Pressler

Kharazmi

Koch

Hoiby

. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. Apmis 2000; 108:329–35.

28.

Hartl

Griese

Kappler

Zissel

Reinhardt

Rebhan

. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006; 117: 204–11.

29.

Sabat

Grutz

Warszawska

Kirsch

Witte

Wolk

. Biology of interleukin-10. Cytokine Growth Factor Rev 2010; 21:331–44.

30.

Honda

Ichiyama

Sunagawa

Maeba

Hasegawa

Furukawa

. Inhaled corticosteroid therapy reduces cytokine levels in sputum from very preterm infants with chronic lung disease. Acta Paediatr 2009; 98:118–22.